Two Sigma Securities LLC purchased a new stake in Zoetis Inc (NYSE:ZTS) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 6,261 shares of the company’s stock, valued at approximately $451,000.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. HealthCor Management L.P. boosted its holdings in shares of Zoetis by 61.8% in the 4th quarter. HealthCor Management L.P. now owns 645,100 shares of the company’s stock valued at $46,473,000 after buying an additional 246,460 shares during the period. Premia Global Advisors LLC acquired a new position in shares of Zoetis in the 4th quarter valued at about $122,000. Robecosam AG boosted its holdings in shares of Zoetis by 4.6% in the 4th quarter. Robecosam AG now owns 15,346 shares of the company’s stock valued at $1,111,000 after buying an additional 679 shares during the period. Terra Nova Asset Management LLC boosted its stake in Zoetis by 15.1% during the 4th quarter. Terra Nova Asset Management LLC now owns 10,130 shares of the company’s stock valued at $730,000 after purchasing an additional 1,330 shares during the period. Finally, Guggenheim Capital LLC boosted its stake in Zoetis by 29.5% during the 4th quarter. Guggenheim Capital LLC now owns 874,308 shares of the company’s stock valued at $62,988,000 after purchasing an additional 199,200 shares during the period. 92.45% of the stock is owned by institutional investors and hedge funds.
Shares of Zoetis Inc (NYSE:ZTS) opened at $84.59 on Wednesday. The firm has a market cap of $40,960.27, a P/E ratio of 48.34, a PEG ratio of 1.89 and a beta of 0.97. Zoetis Inc has a one year low of $52.25 and a one year high of $85.54. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.47 EPS. research analysts anticipate that Zoetis Inc will post 3.04 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be paid a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio is currently 28.57%.
In related news, insider Heidi C. Chen sold 37,453 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $81.02, for a total value of $3,034,442.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 35,663 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the completion of the sale, the executive vice president now owns 49,919 shares in the company, valued at $4,044,437.38. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,569 shares of company stock valued at $8,594,429. Company insiders own 0.31% of the company’s stock.
ZTS has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price for the company. in a research note on Saturday, January 13th. Citigroup raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Thursday, January 4th. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a research note on Monday, January 8th. Cowen set a $80.00 target price on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, November 17th. Finally, Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price for the company in a research note on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $80.28.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/two-sigma-securities-llc-purchases-shares-of-6261-zoetis-inc-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.